Physician profile
Jaydeep Khudai
NPI 1801273362
$4,256.45
in general payments reported to CMS, 2019-2025
33 companies · $746 in 2025
The $746 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $275 · 2021: $548 · 2022: $780 · 2023: $470 · 2024: $815 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,031.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $690.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $652.44 | 2021-2025 | |
| Lilly USA, LLC | $545.62 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $403.13 | 2019-2024 | Spravato, Xarelto |
| Pfizer INC. | $357.18 | 2021-2025 | |
| Allergan, INC. | $259.82 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $165.55 | 2019-2025 | Breztri, Airsupra |
| E.R. Squibb & Sons, L.L.C. | $136.16 | 2022-2024 | Eliquis, Camzyos |
| Exact Sciences Corporation | $134.57 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $83.29 | 2023-2025 | Freestyle Libre 3 |
| Amgen INC. | $82.51 | 2019 | |
| Dynavax Technologies Corporation | $81.92 | 2024 | Heplisav-B |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.73 | 2022-2024 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $79.15 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $55.63 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $54.06 | 2024 | Rexulti |
| Amarin Pharma, INC. | $38.40 | 2020 | |
| Currax Pharmaceuticals LLC | $35.03 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $33.58 | 2019 | |
| Axsome Therapeutics, INC. | $31.12 | 2024 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.95 | 2019-2022 | |
| Corcept Therapeutics | $28.31 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $28.07 | 2021-2025 | |
| Cipher Pharmaceuticals US LLC | $21.53 | 2025 | Natroba, Spinosad |
| Madrigal Pharmaceuticals | $21.38 | 2025 | Rezdiffra |
| Biohaven Pharmaceuticals, INC. | $20.61 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.71 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $16.99 | 2025 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $16.64 | 2023 | Trintellix |
| Glaxosmithkline, LLC. | $15.20 | 2025 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $13.09 | 2021 | |
| Sanofi Pasteur INC. | $12.76 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaydeep Khudai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.